Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Cutia Therapeutics ( (HK:2487) ) is now available.
Cutia Therapeutics has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The board has established three committees: the Audit Committee, Remuneration Committee, and Nomination Committee, each with designated members and chairpersons. This announcement reflects the company’s governance structure and may influence its strategic direction and stakeholder confidence.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
More about Cutia Therapeutics
Cutia Therapeutics is a company incorporated in the Cayman Islands with limited liability, operating in the healthcare industry. It focuses on developing and providing therapeutic solutions, with a market focus that is not explicitly detailed in the release.
Average Trading Volume: 1,252,347
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$3.14B
For a thorough assessment of 2487 stock, go to TipRanks’ Stock Analysis page.